Now PlayingEP. 1 FDA Approves TAS-102, New Nivolumab Breakthrough Designation, Two Priority Reviews, and More
November 16th, 2026Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRCOnvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.Read more
November 12th, 2026GI Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in October 2026Check out this October recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.Read more
November 18th, 2026NATALEE, DeLLphi-305, INTerpath-001, and LITESPARK-012 Headline Key Oncology Data From ESMO 2026Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.Read more
November 17th, 2026Long-Term SANO Data Reinforce Active Surveillance as an Option in Esophageal Cancer Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.Read more
November 16th, 2026Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic CancerThe European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.Read more
November 14th, 2026The OncFive: Top Oncology Articles for the Week of 11/8The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.Read more
November 13th, 2026CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 InhibitionA European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.Read more
November 11th, 2026LITESPARK-022 PRO Data Further Support Adjuvant Belzutifan Plus Pembrolizumab in ccRCCThomas Powles, MBBS, MRCP, MD, discusses LITESPARK-022 QOL findings and patient selection for adjuvant belzutifan plus pembrolizumab in RCC.Read more